Idera Pharmaceuticals Present Positive Phase I Data for their Drug candidate IMO-2125 Idera Pharmaceuticals announced final results from the dose-selection phase of an ongoing Phase 1/2 trial inves...
Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has an...
Find MoreLoom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year ...
Find MoreAllergan can finally sell its losing stake in Teva. Will it? Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair’s $40 billion-plus generics deal, currently stands as Teva’s largest shareholder. Those shares, worth $5.3 billion when Allergan acquired them, have been locked do...
Find MoreSamsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...
Find MoreGilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports Gilead Sciences thought it had prevailed in a whistleblower lawsuit alleging it circumvented FDA rules to use a China-made active ingredient in three top HIV meds, rather than a higher-priced version from South Korea that the agency had a...
Find MoreJohnson & Johnson nabs another combo approval for myeloma star Darzalex Late last year, Johnson & Johnson widened Darzalex’s reach with some combo approvals. And now, it’s adding to that roster. The medication has snagged a green light for use in tandem with chemo drug dexamethasone and Celgene’s Pomalyst fo...
Find MoreTesaro and its new med Zejula are on the block, but bidders aren't rushing in Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal. That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med ...
Find MoreRoche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis (IPF) market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since the FDA green-lighted the medications in October 2014. And this week, both drugmak...
Find MoreMerck's Remicade discounting put squeeze on biosims—and broke U.K. law, officials say Under biosimilar assault in Europe, Merck rolled out cut-rate deals on Remicade to defend its brand from cheaper options, then-brand-new to the market. Now, the U.K.’s competition authority claims the pharma giant “broke competitio...
Find MorePostoperative Pain is the pain that an individual experiences after a major operation or surgical pr.....
Find MoreAcromegaly is a rare, slowly progressive disorder that is caused when the pituitary glands produce t.....
Find MoreSystemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system of the body mist.....
Find MoreEnd-Stage Renal Disease (ESRD) occurs when chronic kidney disease (CKD) has reached the stage where .....
Find MoreAcute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes low blood oxygen......
Find MoreThe gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.